Next 10 |
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the 27 th A...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Van Lanscho...
Support from existing investors including Redmile Group, Invus, Sofinnova Partners and a large investment management firm Financing will enable the Company to extend its cash runway through the end of 2025 Regulatory News: Sensorion (FR0012596468 – ALSEN) ...
2024-04-02 12:25:47 ET More on RiverNorth Flexible Municipal Income Fund Dividend scorecard for RiverNorth Flexible Municipal Income Fund Read the full article on Seeking Alpha For further details see: RiverNorth Flexible Municipal Income Fund declares $0.0954 di...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the publication of...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Bioprocessi...
Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, announces that it is today publishin...
Milestone achieved for SENS-501 gene therapy program with Clinical Trial Application approval in Europe (France as first country) Communication on first patient expected in H2 2024 GJB2 gene therapy program advancing towards Clinical Trial Applications filing expected ...
Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible with potential therapeutic efficacy Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology comp...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, will publish its 2023 financial results on March 14,...
News, Short Squeeze, Breakout and More Instantly...
RiverNorth Flexible Municipal Income Fund Inc. Company Name:
RFM Stock Symbol:
NYSE Market:
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the 27 th A...
Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces its participation in the Van Lanscho...
Support from existing investors including Redmile Group, Invus, Sofinnova Partners and a large investment management firm Financing will enable the Company to extend its cash runway through the end of 2025 Regulatory News: Sensorion (FR0012596468 – ALSEN) ...